The Crypto That’s Making Wall Street Sweat

The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.

Click here to discover our #1 crypto for the market right now – poised for massive growth

Scott W. Morrison net worth and biography

Scott Morrison Biography and Net Worth

Director of Global Blood Therapeutics

Mr. Morrison has served as a member of GBT’s board of directors since January 2016. He had a 35-year career in public accounting, serving public and private companies in the life sciences sector. Mr. Morrison was a partner at Ernst & Young LLP and served as its U.S. life sciences leader. He has worked on hundreds of public and private financings, including more than 40 IPOs and 100 follow-on offerings. He is considered an expert in the M&A arena. Mr. Morrison currently serves on the boards of directors of Audentes Therapeutics, Corvus Pharmaceuticals and Symic Bio. He has served on numerous life sciences industry boards, including the Biotechnology Innovation Organization (BIO) ECS Board, the Bay Area Bioscience Center, the California Life Sciences Foundation, and the Biotechnology Institute. Mr. Morrison holds a B.S. in accounting and finance from the University of California, Berkeley. He is a certified public accountant (inactive).

How do I contact Scott W. Morrison?: The corporate mailing address for Mr. Morrison and other Global Blood Therapeutics executives is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Global Blood Therapeutics can also be reached via phone at (650) 741-7700 and via email at [email protected]. Learn More on Scott W. Morrison's contact information.
Has Scott W. Morrison been buying or selling shares of Global Blood Therapeutics?: Scott W. Morrison has not been actively trading shares of Global Blood Therapeutics over the course of the past ninety days. Most recently, Scott W. Morrison sold 4,800 shares of the business's stock in a transaction on Thursday, September 9th. The shares were sold at an average price of $30.21, for a transaction totalling $145,008.00. Learn More on Scott W. Morrison's trading history.
Who are Global Blood Therapeutics' active insiders?: Global Blood Therapeutics' insider roster includes Eric Fink (Insider), Scott Morrison (Director), and Philip Pizzo (Director). Learn More on Global Blood Therapeutics' active insiders.

Scott W. Morrison Insider Trading History at Global Blood Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/9/2021	Sell	4,800	$30.21	$145,008.00

Scott W. Morrison Buying and Selling Activity at Global Blood Therapeutics

Global Blood Therapeutics Company Overview

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Today's Range

Now: $68.49

$68.49

50 Day Range

MA: $68.47

$68.07

$68.49

2 Week Range

Now: $68.49

$21.65

$73.02

Volume

74 shs

Average Volume

2,065,836 shs

Market Capitalization

$4.62 billion

P/E Ratio

N/A

Dividend Yield